ADEKA (4401) FY2027 Q1 Earnings Report

Quick View

Executive Summary

The key highlights of the current results were revenue growth centered on the Chemicals Business and a significant improvement in profit margins, resulting in a strong start in terms of profit performance relative to the full-year forecast. Revenue was ¥117.04B (+15.2% YoY), Operating Income was ¥15.69B (+42.7%), Ordinary Income was ¥16.62B (+50.2%), and Net Income attributable to the consolidated group was ¥12.50B (+44.5%). Against a ¥15.44B increase in revenue, the increase in Operating Income was ¥4.69B, indicating that revenue growth translated into strong profit growth. The Operating Margin improved from 10.8% to 13.4%, with the effects of higher revenue and control of SG&A expenses driving profit growth.

Factors Affecting Business Performance

【Revenue】Revenue was ¥117.04B (+15.2% YoY), with the Chemicals Business (¥62.87B, +19.9%) and Life Sciences Business (¥31.09B, +14.6%) driving growth. The Food Business remained a low-growth segment at ¥21.47B (+4.3%).

【Profit and Loss】Operating Income rose significantly to ¥15.69B (+42.7%), Ordinary Income to ¥16.62B (+50.2%), and Net Income attributable to the consolidated group to ¥12.50B (+44.5%). The gross margin improved to 30.3% (28.5% in the same period of the previous year), while the 9.9% increase in SG&A expenses was below the 15.2% revenue growth rate, resulting in operating leverage. Non-operating income included foreign exchange gains of ¥0.84B and interest income of ¥0.72B, which boosted Ordinary Income. Extraordinary gains and losses resulted in a net loss of ¥0.13B, indicating that one-time factors were limited. Net Income attributable to owners of the parent of ¥10.71B reflects ¥1.79B attributable to non-controlling interests and ¥3.99B in income taxes and other taxes. Accordingly, the current period achieved both revenue and profit growth, and the quality of profit growth can be viewed as high, primarily due to improvements in the core business.

Segment Analysis

The Chemicals Business recorded Revenue of ¥62.87B (+19.9% YoY), Operating Income of ¥10.15B (+60.9%), and a margin of 16.1% (12.0% in the same period of the previous year), showing significant improvement and becoming the core business, accounting for approximately 65% of consolidated Operating Income. The Life Sciences Business continued to improve, with Revenue of ¥31.09B (+14.6%), Operating Income of ¥4.49B (+36.9%), and a margin of 14.4% (12.1% in the same period of the previous year). The Food Business increased Revenue to ¥21.47B (+4.3%), but profitability deteriorated, with Operating Income of ¥0.86B (-21.7%) and a margin of 4.0% (5.3% in the same period of the previous year). The Other Businesses recorded Revenue of ¥6.10B (+28.7%) and Operating Income of ¥0.21B (-15.1%). Rising margins in the Chemicals and Life Sciences Businesses and deteriorating profitability in the Food Business are widening the profitability gap among segments.

Key Financial Indicators

【Profitability】The Operating Margin improved to 13.4% (10.8% in the same period of the previous year), the Net Profit Margin improved to 9.2% (7.1%), and the gross margin rose to 30.3% (28.5%). Annualized ROE remained high at 13.1%.【Cash Quality】Cash and deposits amounted to ¥98.61B, increasing from the previous year, while accounts receivable of ¥116.27B and inventories of ¥73.56B warrant monitoring from an asset-efficiency perspective.【Investment Efficiency】Total assets were ¥576.09B, increasing only 2.9% YoY. As this growth was below the profit growth rate, asset efficiency has generally been maintained.【Financial Soundness】The Equity Ratio was high at 66.1%, and the financial foundation was conservative, with current assets of ¥360.80B substantially exceeding current liabilities of ¥125.84B.

Cash Flow Analysis

As no cash flow statement has been disclosed, cash trends are analyzed based on changes in the balance sheet. Cash and deposits increased 2.1% YoY to ¥98.61B, indicating that the funding base has been maintained even during a period of earnings expansion. Property, plant and equipment was ¥132.26B (+0.4% YoY), remaining largely flat, with no evidence of a major expansion in investment. Investment securities increased to ¥58.47B, up ¥1.79B YoY (+17.9%), increasing sensitivity to changes in market prices. Long-term borrowings declined 24.2% YoY to ¥17.96B, indicating a trend toward reducing interest-bearing debt. Treasury stock decreased by ¥14.497B, from ¥18.99B (negative) in the same period of the previous year to ¥4.50B (negative), representing a significant change in the shareholders’ equity structure. Overall, funds were allocated to both business expansion and capital policy, while cash levels remained stable.

Earnings Quality

Operating Income of ¥15.69B forms the basis of Ordinary Income of ¥16.62B, indicating that profit growth was driven by expansion of the core business. Non-operating income of ¥2.78B represented only 2.4% of revenue and consisted of foreign exchange gains of ¥0.84B, interest income of ¥0.72B, and dividend income of ¥0.39B, while non-operating expenses included interest expense of ¥0.87B. The ¥0.13B difference between Ordinary Income and profit before tax corresponds to net extraordinary factors consisting of a ¥0.09B gain on the sale of fixed assets and ¥0.21B in extraordinary losses. Net Income attributable to owners of the parent of ¥10.71B was below Ordinary Income, primarily due to ¥3.99B in income taxes and other taxes and ¥1.79B attributable to non-controlling interests; dependence on one-time items was limited. Comprehensive Income of ¥20.36B substantially exceeded Net Income, and increases of ¥5.40B in valuation difference on available-for-sale securities and ¥1.99B in foreign currency translation adjustments boosted net assets. This should be noted as a factor of fluctuation separate from net income for the period.

Earnings Forecast and Guidance

The full-year forecast is Revenue of ¥462.00B (+10.9%), Operating Income of ¥50.00B (+20.1%), and Ordinary Income of ¥50.00B (+16.9%), and the Company revised both its earnings forecast and dividend forecast during the quarter. Q1 progress rates were 25.3% for Revenue, 31.4% for Operating Income, 33.2% for Ordinary Income, and 33.5% for Net Income, all exceeding the standard progress benchmark of 25%. In particular, profit progress exceeded revenue progress, with the Q1 improvement in gross margin and control of SG&A expenses serving as the background to the upside. Achieving the full-year plan will depend on the continuation of high margins in the Chemicals Business and profitability improvements in the Food Business.

Shareholder Returns

The full-year dividend forecast per share is ¥132.00, and the full-year EPS forecast is ¥329.98, resulting in an estimated Payout Ratio of approximately 40.0%. This level does not represent an excessive burden based solely on dividends and is consistent with profit growth. Treasury stock decreased by ¥14.497B, from ¥18.99B (negative) in the same period of the previous year to ¥4.50B (negative), representing a significant change in capital policy; however, the breakdown among acquisitions, disposals, and cancellations cannot be identified from the available data, and therefore the Total Return Ratio including dividends has not been calculated.

Risk Factors

1. Concentration of profit in the Chemicals Business: The Chemicals Business generated segment profit of ¥10.15B, accounting for approximately 65% of consolidated Operating Income of ¥15.69B. Consequently, fluctuations in demand, raw material and fuel costs, and product mix in this business could have a substantial impact on company-wide profit.

2. Deterioration in working capital efficiency: The high balances of accounts receivable of ¥116.27B and inventories of ¥73.56B constrain capital efficiency, making it necessary to monitor whether earnings growth converts into cash generation.

3. Deteriorating profitability in the Food Business: While Revenue in the Food Business increased +4.3%, segment profit declined -21.7%, and its margin fell to 4.0% (5.3% in the same period of the previous year). Continued cost increases or deterioration in the sales mix could weigh on profit recovery.

Industry Benchmark (For Reference; Compiled by the Company)

Key Points from the Earnings Results

1. Operating Income increased +42.7% against Revenue growth of +15.2%, and the Operating Margin improved to 13.4% (10.8% in the same period of the previous year). The background was operating leverage resulting from higher margins in the Chemicals Business and relatively restrained SG&A expenses.

2. Segment profit in the Chemicals Business increased +60.9%, contributing approximately 65% of consolidated Operating Income and serving as the core business driving profit growth during the current period.

3. While the full-year progress rates of 31.4% for Operating Income and 33.5% for Net Income exceeded the standard progress benchmark of 25%, the widening structural profitability gap among segments, particularly the deteriorating profitability of the Food Business, will be an area to monitor in future earnings data.

Theoretical Share Price (Reference Value)

Sensitivity: ¥3,790–¥4,011 at ±1% for the cost of equity, and ¥3,897–¥3,899 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the end of the quarter are used (there is a timing difference relative to the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat on the high side.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---